Grochans S, Cybulska AM, Siminska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme–literature review. Cancers. 2022;14:2412.
Article PubMed PubMed Central Google Scholar
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification Of Tumors Of The Central Nervous System: a summary. Neuro Oncol. 2021;23:1231–51.
Article CAS PubMed PubMed Central Google Scholar
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.
Delgado-Lopez PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18:1062–71.
Article CAS PubMed Google Scholar
Nizamutdinov D, Stock EM, Dandashi JA, Vasquez EA, Mao Y, Dayawansa S, et al. Prognostication of survival outcomes in patients diagnosed with glioblastoma. World Neurosurg. 2018;109:e67-74.
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.
Article CAS PubMed Google Scholar
Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, et al. A prospective phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. J Neurosurg. 2016;124:1300–9.
Article CAS PubMed Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Article CAS PubMed Google Scholar
de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, et al. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20:710–20.
Article PubMed PubMed Central Google Scholar
Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10:3728–36.
Article CAS PubMed Google Scholar
Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, et al. Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Rep. 2017;19:1858–73.
Article CAS PubMed PubMed Central Google Scholar
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262–7.
Article CAS PubMed PubMed Central Google Scholar
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet. 1995;345:1008–12.
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88.
Article CAS PubMed PubMed Central Google Scholar
Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev 2011;3:CD007294.
Gawley M, Almond L, Daniel S, Lastakchi S, Kaur S, Detta A, et al. Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme. J Control Release. 2020;324:1–16.
Article CAS PubMed Google Scholar
Ramesh M, Ahlawat P, Srinivas N. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24:104–23.
Xu Y. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841–51.
Article CAS PubMed Google Scholar
Sinha B. Topoisomerase Inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 23:831–36.
Vrendenburgh J, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11:80–9.
Saunders A, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer. 2006;95:131–8.
Article CAS PubMed PubMed Central Google Scholar
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516–25.
Article CAS PubMed Google Scholar
Turner CD, Gururangan S, Eastwood J, Bottom K, Watral W, Beason R, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. 2004;4:102–8.
Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, et al. Irinotecan treatment for recurrent malignant glioma using an every-three-week regimen. Am J Clin Oncol. 2002;25:204–8.
Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer. 2003;97:2352–8.
Article CAS PubMed Google Scholar
Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003;14:603–14.
Article CAS PubMed Google Scholar
Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56:183–8.
Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97–11. Neuro Oncol. 2004;6:21–7.
Article CAS PubMed PubMed Central Google Scholar
Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940–9.
Yung WKA, Lieberman FS, Wen P, Robin I, Gilbert M, Chang S, et al. Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study. J Clin Oncol. 2005;23:1521–621.
Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol. 2004;27:33–8.
Article CAS PubMed Google Scholar
Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22:4779–86.
Article CAS PubMed Google Scholar
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004;6:145–53.
留言 (0)